Express News | Citi: Maintains Buy rating on Hutchmed (China), Target Price raised to HKD 42.

BreakingsJan 3 14:28

Citi raised the Target Price for Hutchmed (China) (00013.HK) to 42 Hong Kong dollars, maintaining a "Buy" rating.

Hutchmed (China) (00013.HK) announced yesterday (2nd) that the new drug application for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) has been accepted by the National Medical Products Administration and granted priority review. Citigroup published a research report indicating that the combination therapy has advantages over peers, including specific biomarker MET high levels and being an oral regimen without chemotherapy. The report also mentioned that the company sold its 45% stake in Hutchison China MediTech for 0.608 billion USD.

AASTOCKSJan 3 10:28

GF SEC: Maintain the "Buy" rating for Hutchmed (China) (00013) with a fair value of 41.35 HKD.

GF SEC expects Hutchmed (China) to achieve a net income of 0.005, 0.02, and 0.074 billion USD for the years 2024-2026 respectively.

Zhitong FinanceJan 3 09:22 · Ratings

Sector Update: Health Care Stocks Edge Higher Premarket Thursday

MT NewswiresJan 2 22:12

HUTCHMED Shares Are Trading Higher After the Company Announced the Divestment of Its 45% Interest in Shanghai Hutchison Pharmaceuticals.

BenzingaJan 2 21:01

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

BenzingaJan 2 20:38